Value-added anticancer reactivity of sub-5 nm Ag-drug nanoparticles derived from organosilver (Ⅰ) MOF

作     者：Chao-Yu Song Jia-Yuan Zhang Yuan Qiu Hai-Ping Jin Hui-Ming Zhang Shuang Liu Hong Liu Hong-Bin Qiu Guang-Gang Gao 

作者机构：School of Basic Medicine Jiamusi University School of Materials Science and Engineering University of Jinan School of Public Health Jiamusi University 

出 版 物：《Science China Chemistry》 (中国科学（化学英文版）)

年 卷 期：2019年第62卷第3期

页      面：347-354页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 10[医学] 0702[理学-物理学] 

基　　金：supported by the National Natural Science Foundation of China (21271034, 31471312) the Heilongjiang Provincial Natural Science Foundation (B2017013) the Shandong Provincial Natural Science Foundation (ZR2017MEM003) the Principal Innovation and Entrepreneurship of Jiamusi University (XZYF2017-21) the Science and Technology Innovation Team Program of Jiamusi University (CXTD 2016-01) Application Foundation and Advanced Technology Program of Jiamusi University (yzz2014-002) 

主　　题：erlotinib silver nanocluster targeting A549 cell supramolecular 

摘      要：A totally structure-determined organosilver(I) metal-oganic framework(MOF) of [{Ag_(18)(CF_3COO)_(18)(H_2O)_2}{Ag_4(erlotinib)_4}]_n·7nCH_3OH·3nH_2O(1) was first synthesized by the self-assembly of erlotinib drug ligand and silver salts in the study. 1 formed a NbO-like 3D network, which was built from Ag(I)-erlotinib induced chains and 18-core silver(I) nanoclusters. When 1 was dispersed in methanol solution, it formed derivative nanoparticles(1-NPs) with the average size of 3.81 nm. Silver(Ⅰ) ion is an efficient reactive oxygen species(ROS) evocator, whereas the erlotinib ligand possesses the targeting activity towards tumor cells. Therefore, IC_(50) values of 1-NPs for A549 and MRC-5 cells were respectively 0.97 and 7.28 μM, which were lower than IC_(50) value of erlotinib. It should be noted that the 7.5-fold higher inhibition effect on A549 cells allows 1-NPs to be a potential targeting anticancer drug for curing lung cancer. The study opens a new avenue to design anticancer drugs based on organosilver(I)MOF derivatives that can realize the value-added reactivity by combining clinical drugs with ROS-inductive silver(Ⅰ) ion.